FDA approves futibatinib for cholangiocarcinoma

The FDA granted accelerated approval to futibatinib for certain patients with cholangiocarcinoma.The indication applies to use of the agent by adults with previously treated, unresectable, locally advanced or metastatic intrahepatic cholangiocarcinoma who harbor fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements.Futibatinib (Lytgobi, Taiho Oncology) is a selective FGFR1-4 inhibitor.The multicenter, open-label, single-arm TAS-120-101 trial assessed the efficacy of futibatinib for 103 patients with previously treated, unresectable, locally advanced or metastaticRead More